Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
about
The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker valueFulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complexRelationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer linesInverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivityEpidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferationThe mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cellsVAV3 mediates resistance to breast cancer endocrine therapy.The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer.Identifying cancer biomarkers by network-constrained support vector machines.Estrogen-induced apoptosis of breast epithelial cells is blocked by NO/cGMP and mediated by extranuclear estrogen receptors.Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways.Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patientsCytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancerTNF-α converting enzyme-mediated ErbB4 transactivation by TNF promotes colonic epithelial cell survivalElevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Headway in resistance to endocrine therapy in breast cancer.ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer.ADAM12 induces estrogen-independence in breast cancer cells.Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancerZinc and cancer: implications for LIV-1 in breast cancer.Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinaseDasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.KSHV activation of VEGF secretion and invasion for endothelial cells is mediated through viral upregulation of emmprin-induced signal transduction.Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future DirectionsNek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitApoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen species.Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.Ubiquitin ligase c-Cbl is involved in tamoxifen-induced apoptosis of MCF-7 cells by downregulating the survival signals.
P2860
Q26782620-D8C08A7B-45A3-4CF7-A5B5-1D8C15903C12Q28301066-74F5EAB7-21AB-4792-86AE-83CC29EA1427Q28542662-97249BA2-FCCE-412E-87CB-310C719FA152Q31134061-85422179-F152-43E6-8337-B72C1FF72C98Q33572280-F326AB0D-23A1-4D28-99B9-1DE1421F1F7BQ33612070-9BB867F8-E84E-48B5-AFA3-B28564D627D4Q33759691-F7F8921B-0E94-4FCC-93C4-B97FCFF55B7FQ33759701-C7ED67DA-5AED-46AC-98F7-E12648BAE47BQ33827037-9F12E8DC-9ACA-41F0-AC27-6E09205D2EA4Q33977133-419BFDC8-E1B8-43EC-8A5C-18EA712542D6Q34025167-C72668A0-151A-4425-BB81-944CDCA7685AQ34047245-70B9D1C6-87B4-41ED-A707-9E295EEDB2A4Q34392623-D3F352B6-30DF-424B-87B5-110F45FB61CBQ34461019-95A3E5E0-F70B-4468-940A-23FF9DA4C53EQ34577504-F2CFAEB1-E747-4097-8FF9-E8571A6A4263Q34657786-DC067064-F0F9-45D0-A122-31171EB4044DQ35000307-8F6A67FF-34AA-457F-A728-F579CEC8700AQ35088147-9D9D9502-5A3C-4CCE-B162-ECA27A00C29CQ35118166-B08247C1-313E-414A-8AA1-49F911D939CDQ35128098-258C200B-26F8-4AB4-9D47-529C3F72FC7CQ35159615-5594D78E-FB97-42C0-8BB9-213034DBD11DQ35558050-9B35674F-8FF0-4ABF-8562-F03CB9625D17Q35558954-9CD4E171-35CD-443E-9470-C0002478EEE1Q35667708-5F253EF0-A765-4EC3-ADDF-2760FF464E1EQ35755192-1D8AC742-FA9D-42AB-AAA3-DB2AA91206E4Q35889618-E0028865-8554-4088-8E7F-AB7B1301C3DDQ36054273-5A0936EF-EE02-4383-8C03-43F395C41334Q36067934-AC3F8AEE-8A72-43A2-93E5-A38548567A52Q36126413-BA5A4185-A6CD-47BE-8E23-3607C9C1CC1AQ36135818-E2A9C942-FFC0-4476-99BC-FDDA134969BDQ36212765-CDA42588-6D10-4ECE-9BE6-C08ACB8AB0CEQ36457808-71C68D9E-1C60-4668-8758-DE599D3F3951Q36629854-500A9CEE-FC4C-425B-8455-77EF3C6C3732Q37723758-A0B8047B-1B56-44CB-A3CB-720ACD43603CQ38223222-F21AFB04-4304-404B-92E3-BFEBFE063802Q38980243-38529B23-2F08-4B4B-8C88-5E402E307892Q39172020-7821707D-C4F1-4E59-873C-C461ED141B53Q39251248-2D4EE884-B5F2-43FC-AB56-E03F9211BF8BQ39345249-4A3D4B60-F10F-4716-867F-860AFD45BD34Q39617513-67C1FE9C-3EF6-4B12-AA61-91A00A319A7B
P2860
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Endocrine resistance associate ...... r PI3K/Akt signaling pathways.
@en
Endocrine resistance associate ...... r PI3K/Akt signaling pathways.
@nl
type
label
Endocrine resistance associate ...... r PI3K/Akt signaling pathways.
@en
Endocrine resistance associate ...... r PI3K/Akt signaling pathways.
@nl
prefLabel
Endocrine resistance associate ...... r PI3K/Akt signaling pathways.
@en
Endocrine resistance associate ...... r PI3K/Akt signaling pathways.
@nl
P2093
P2860
P356
P1476
Endocrine resistance associate ...... or PI3K/Akt signaling pathways
@en
P2093
Julie A Vendrell
Pascale A Cohen
Sabrina Ben Larbi
Sandra E Ghayad
P2860
P304
P356
10.1002/IJC.24750
P577
2010-01-01T00:00:00Z